Abstract
We previously demonstrated that the intraperitoneal administration of palmitoylethanolamide (PEA) in mice with chronic constriction injury of the sciatic nerve evoked a relief of both thermal hyperalgesia and mechanical allodynia in neuropathic mice. Since diabetic neuropathy is one of the most common long-term complications of diabetes, we explored the ability of PEA to also relief this kind of chronic pain, employing the well established streptozotocin-induced animal model of type 1 diabetes. Our findings demonstrated that PEA relieves mechanical allodynia, counteracts nerve growth factor deficit, improves insulin level, preserves Langherans islet morphology reducing the development of insulitis in diabetic mice. These results suggest that PEA could be effective in type1 -diabetic patients not only as pain reliever but also in controlling the development of pathology.
Keywords: Allodynia, diabetes, endocannabinoid, insulin, insulitis, mast cell, nerve growth factor, neuropathy, oxidative stress, Palmitoylethanolamide.
CNS & Neurological Disorders - Drug Targets
Title:Palmitoylethanolamide Relieves Pain and Preserves Pancreatic Islet Cells in a Murine Model of Diabetes
Volume: 14 Issue: 4
Author(s): Giulia Donvito, Isabella Bettoni, Francesca Comelli, Anita Colombo and Barbara Costa
Affiliation:
Keywords: Allodynia, diabetes, endocannabinoid, insulin, insulitis, mast cell, nerve growth factor, neuropathy, oxidative stress, Palmitoylethanolamide.
Abstract: We previously demonstrated that the intraperitoneal administration of palmitoylethanolamide (PEA) in mice with chronic constriction injury of the sciatic nerve evoked a relief of both thermal hyperalgesia and mechanical allodynia in neuropathic mice. Since diabetic neuropathy is one of the most common long-term complications of diabetes, we explored the ability of PEA to also relief this kind of chronic pain, employing the well established streptozotocin-induced animal model of type 1 diabetes. Our findings demonstrated that PEA relieves mechanical allodynia, counteracts nerve growth factor deficit, improves insulin level, preserves Langherans islet morphology reducing the development of insulitis in diabetic mice. These results suggest that PEA could be effective in type1 -diabetic patients not only as pain reliever but also in controlling the development of pathology.
Export Options
About this article
Cite this article as:
Donvito Giulia, Bettoni Isabella, Comelli Francesca, Colombo Anita and Costa Barbara, Palmitoylethanolamide Relieves Pain and Preserves Pancreatic Islet Cells in a Murine Model of Diabetes, CNS & Neurological Disorders - Drug Targets 2015; 14 (4) . https://dx.doi.org/10.2174/1871527314666150429111537
DOI https://dx.doi.org/10.2174/1871527314666150429111537 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibition of Early Upstream Events in Prodromal Alzheimer’s Disease by Use of Targeted Antioxidants
Current Aging Science The Interplay between the Gut Immune System and Microbiota in Health and Disease: Nutraceutical Intervention for Restoring Intestinal Homeostasis
Current Pharmaceutical Design TRP Channels: New Potential Therapeutic Approaches in CNS Neuropathies
CNS & Neurological Disorders - Drug Targets Advanced Drug Delivery of N-Acetylcarnosine (N-Acetyl-beta-alanyl-Lhistidine), Carcinine (Beta-alanylhistamine) and L-carnosine (Beta-alanyl- L-histidine) in Targeting Peptide Compounds as Pharmacological Chaperones for Use in Tissue Engineering, Human Disease Management and Therapy: From in vitro to the Clinic
Recent Patents on Drug Delivery & Formulation Structures Required of Polyphenols for Inhibiting Advanced Glycation end Products Formation
Current Drug Metabolism Regulation of Vascular Genes by Glucose
Current Pharmaceutical Design Autoimmune Channelopathies of the Nervous System
Current Neuropharmacology Plasma Glucose Lowering Activity of Palmatine and its Effect on Liver, Kidney and Antioxidant Enzymes Parameters in STZ Induced Diabetic Rat Model
Current Bioactive Compounds T-Lymphocytes: A Target for Stimulatory and Inhibitory Effects of Zinc Ions
Endocrine, Metabolic & Immune Disorders - Drug Targets Antihyperglycemic Effects of Formulation of Spray Dried Fruit Juice of Emblica officinalis in Streptozotocin Induced Diabetic Rats.
Current Nutrition & Food Science Glaucoma and Aging
Current Aging Science Sonic Hedgehog Pathway as a Target for Therapy in Angiogenesis-Related Diseases
Current Signal Transduction Therapy Chemopreventive Properties and Molecular Mechanisms of the Bioactive Compounds in Hibiscus Sabdariffa Linne
Current Medicinal Chemistry Bioartificial Pancreas: Drug Delivery through Islet Microencapsulation to Treat Diabetes
Recent Patents on Biomedical Engineering (Discontinued) VR1 Receptor Modulators as Potential Drugs for Neuropathic Pain
Mini-Reviews in Medicinal Chemistry The Impact of Physical Activity on Mitigation of Health Care Costs Related to Diabetes Mellitus: Findings from Developed and Developing Settings
Current Diabetes Reviews Chemical Metabolic Inhibitors for the Treatment of Blood-Borne Cancers
Anti-Cancer Agents in Medicinal Chemistry Arterial Stiffness and Type 1 Diabetes: The Current State of Knowledge
Current Diabetes Reviews Superior Neuroprotective Effects of Cerebrolysin in Nanoparticle-Induced Exacerbation of Hyperthermia-Induced Brain Pathology
CNS & Neurological Disorders - Drug Targets The Promotional Effect of Mesenchymal Stem Cell Homing on Bone Tissue Regeneration
Current Stem Cell Research & Therapy